Literature DB >> 20466571

Breakfast with glycomacropeptide compared with amino acids suppresses plasma ghrelin levels in individuals with phenylketonuria.

Erin L MacLeod1, Murray K Clayton, Sandra C van Calcar, Denise M Ney.   

Abstract

Phenylketonuria (PKU) requires a lifelong low-phenylalanine (phe) diet where protein needs are met by consumption of a phe-free amino acid (AA) formula; complaints of persistent hunger are common. Foods made with glycomacropeptide (GMP), an intact protein that contains minimal phe and may promote satiety, provide an alternative to AA formula. The objective was to assess the ability of a GMP breakfast to promote satiety and affect plasma concentrations of AAs, insulin, and the appetite stimulating hormone ghrelin in those with PKU, when compared to an AA-based breakfast. Eleven PKU subjects (8 adults and 3 boys ages 11-14) served as their own controls in an inpatient metabolic study with two 4-day treatments: an AA-based diet followed by a diet replacing all AA formula with GMP foods. Plasma concentrations of AAs, insulin and ghrelin were obtained before and/or 180 min after breakfast. Satiety was assessed using a visual analog scale before, immediately after and 150 min after breakfast. Postprandial ghrelin concentration was significantly lower (p=0.03) with GMP compared to an AA-based breakfast, with no difference in fasting ghrelin. Lower postprandial ghrelin concentrations were associated with greater feelings of fullness after breakfast suggesting greater satiety with GMP compared to AAs. Postprandial concentrations of insulin and total plasma AAs were higher after a GMP breakfast compared to an AA-based breakfast consistent with slower absorption and less degradation of AAs from GMP. These results show sustained ghrelin suppression, and suggest greater satiety with ingestion of a meal containing GMP compared with AAs. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466571      PMCID: PMC2906609          DOI: 10.1016/j.ymgme.2010.04.003

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  46 in total

Review 1.  Biological activities of bovine glycomacropeptide.

Authors:  E P Brody
Journal:  Br J Nutr       Date:  2000-11       Impact factor: 3.718

2.  Whole-body nitrogen and splanchnic amino acid metabolism differ in rats fed mixed diets containing casein or its corresponding amino acid mixture.

Authors:  M Daenzer; K J Petzke; B J Bequette; C C Metges
Journal:  J Nutr       Date:  2001-07       Impact factor: 4.798

Review 3.  Phenylketonuria (PKU): screening and management.

Authors: 
Journal:  NIH Consens Statement       Date:  2000 Oct 16-18

4.  Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations.

Authors:  Heung-Man Lee; Guiyun Wang; Ella W Englander; Masayasu Kojima; George H Greeley
Journal:  Endocrinology       Date:  2002-01       Impact factor: 4.736

5.  Hydrolyzed dietary casein as compared with the intact protein reduces postprandial peripheral, but not whole-body, uptake of nitrogen in humans.

Authors:  Amélie Deglaire; Claire Fromentin; Hélène Fouillet; Gheorghe Airinei; Claire Gaudichon; Claire Boutry; Robert Benamouzig; Paul J Moughan; Daniel Tomé; Cécile Bos
Journal:  Am J Clin Nutr       Date:  2009-08-19       Impact factor: 7.045

6.  Phenylketonuria in adulthood: a collaborative study.

Authors:  R Koch; B Burton; G Hoganson; R Peterson; W Rhead; B Rouse; R Scott; J Wolff; A M Stern; F Guttler; M Nelson; F de la Cruz; J Coldwell; R Erbe; M T Geraghty; C Shear; J Thomas; C Azen
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

7.  A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans.

Authors:  D E Cummings; J Q Purnell; R S Frayo; K Schmidova; B E Wisse; D S Weigle
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

8.  Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery.

Authors:  David E Cummings; David S Weigle; R Scott Frayo; Patricia A Breen; Marina K Ma; E Patchen Dellinger; Jonathan Q Purnell
Journal:  N Engl J Med       Date:  2002-05-23       Impact factor: 91.245

9.  Protein, amino acids, vagus nerve signaling, and the brain.

Authors:  Daniel Tomé; Jessica Schwarz; Nicolas Darcel; Gilles Fromentin
Journal:  Am J Clin Nutr       Date:  2009-07-29       Impact factor: 7.045

10.  Inverse association between the effect of carbohydrates on blood glucose and subsequent short-term food intake in young men.

Authors:  G Harvey Anderson; Nicole L A Catherine; Dianne M Woodend; Thomas M S Wolever
Journal:  Am J Clin Nutr       Date:  2002-11       Impact factor: 7.045

View more
  24 in total

1.  Nutritional status in patients with phenylketonuria using glycomacropeptide as their major protein source.

Authors:  A Pinto; M F Almeida; P C Ramos; S Rocha; A Guimas; R Ribeiro; E Martins; A Bandeira; A MacDonald; J C Rocha
Journal:  Eur J Clin Nutr       Date:  2017-04-12       Impact factor: 4.016

2.  Nutritional Management of Phenylketonuria.

Authors:  Erin L Macleod; Denise M Ney
Journal:  Ann Nestle Eng       Date:  2010-06

Review 3.  Food products made with glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative to amino Acid-based medical foods for nutrition management of phenylketonuria.

Authors:  Sandra C van Calcar; Denise M Ney
Journal:  J Acad Nutr Diet       Date:  2012-08       Impact factor: 4.910

4.  Clinical therapeutics for phenylketonuria.

Authors:  Jaspreet Singh Kochhar; Sui Yung Chan; Pei Shi Ong; Lifeng Kang
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

5.  Glycomacropeptide, a low-phenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria.

Authors:  Patrick Solverson; Sangita G Murali; Adam S Brinkman; David W Nelson; Murray K Clayton; Chi-Liang Eric Yen; Denise M Ney
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-01-31       Impact factor: 4.310

Review 6.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

Review 7.  Advances in the nutritional and pharmacological management of phenylketonuria.

Authors:  Denise M Ney; Robert D Blank; Karen E Hansen
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2014-01       Impact factor: 4.294

8.  Phenylketonuria: nutritional advances and challenges.

Authors:  Marcello Giovannini; Elvira Verduci; Elisabetta Salvatici; Sabrina Paci; Enrica Riva
Journal:  Nutr Metab (Lond)       Date:  2012-02-03       Impact factor: 4.169

Review 9.  Recommendations for the nutrition management of phenylalanine hydroxylase deficiency.

Authors:  Rani H Singh; Fran Rohr; Dianne Frazier; Amy Cunningham; Shideh Mofidi; Beth Ogata; Patricia L Splett; Kathryn Moseley; Kathleen Huntington; Phyllis B Acosta; Jerry Vockley; Sandra C Van Calcar
Journal:  Genet Med       Date:  2014-01-02       Impact factor: 8.822

Review 10.  New Strategies for the Treatment of Phenylketonuria (PKU).

Authors:  Pietro Strisciuglio; Daniela Concolino
Journal:  Metabolites       Date:  2014-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.